Abstract
Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
| Original language | English |
|---|---|
| Pages (from-to) | 189-198 |
| Number of pages | 10 |
| Journal | Core Evidence |
| Volume | 2 |
| Issue number | 3 |
| Publication status | Published - 2008 |
Fingerprint
Keywords
- Cardiovascular risk factors
- Diabetes
- Metformin
- Outcomes
- Pioglitazone
ASJC Scopus subject areas
- Medicine(all)
- Reviews and References, Medical
- Pharmacology
Cite this
Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus : An evidence-based review of its place in therapy. / Derosa, Giuseppe; Salvadeo, S. A T.
In: Core Evidence, Vol. 2, No. 3, 2008, p. 189-198.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus
T2 - An evidence-based review of its place in therapy
AU - Derosa, Giuseppe
AU - Salvadeo, S. A T
PY - 2008
Y1 - 2008
N2 - Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
AB - Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
KW - Cardiovascular risk factors
KW - Diabetes
KW - Metformin
KW - Outcomes
KW - Pioglitazone
UR - http://www.scopus.com/inward/record.url?scp=65849142786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65849142786&partnerID=8YFLogxK
M3 - Article
C2 - 21221185
AN - SCOPUS:65849142786
VL - 2
SP - 189
EP - 198
JO - Core Evidence
JF - Core Evidence
SN - 1555-1741
IS - 3
ER -